



PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

*Complete if Known*

Application Number	10/081,348
Filing Date	February 22, 2002
First Named Inventor	Oliver Cussenot
Art Unit	
Examiner Name	Not Yet Assigned

Attorney Docket Number EGYP 3.9-021 CONT

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number-Kind Code <sup>4</sup> (if known)				
KAC	A	-WO 98/05797-	02-12-1988	Calydon		
	B	-WO 98/16628-	04-23-1998	The Regents of the University of California		
✓	C	-WO 97/35616-	10-02-1997	Pacific Northwest Cancer Foundation		

Examiner Signature

*Karen Q. Canille*

Date Considered

*11/19/2004*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

				Complete if Known	
				Application Number	10/081,348
				Filing Date	February 22, 2002
				First Named Inventor	Oliver Cussenot
				Group Art Unit	
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	EGYP 3.9-021 CONT

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<sup>2</sup>
D	Sato et al., Metastatic and androgen-sensitive human prostate cancer animal model using orthotopic inoculation of LNCaP cells in SCID mice, 155 J. Urology, No. 5 Suppl. (1996)		✓
E	Cussenot et al., 214 Experimental Cell Research, 83-92 (1994)		✓
F	Eaton et al., Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: isolation and characterization of neoplastic prostatic epithelial cell line CPA 1, 12 The Prostate, No. 2, 129-143 (1988)		✓
G	Anz et al., Surgical Orthotopic Implantation Allows High Lung and Lymph Node Metastatic Expression of Human Prostate Carcinoma Cell Line PC-3 in Nude Mice, 34 Prostate No. 3, 169-174 (1988)		✓
H	Van Weerden et al., Development of seven new human prostate tumor xenograft models and their histopathological characterization, 149 Am. J. Pathology, No. 3, (September 1996)		✓
I	Israeli et al., Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen, 53 Cancer Research, No. 2 227-230 (1993)		✓
J	J.W. Aquila et al., 36 The Prostate, 189-93 (1998)		✓
K	Anidjar Maurice et al., In vivo model mimicking natural history of dog prostate cancer, 46 Prostate No. 1, 2-10 (2001)		✓
L	Navone et al., Model Systems of Prostate Cancer: Uses and Limitations, 17 Cancer Metastasis No. 4, 361-71 (1999)		✓
M	Horoszewicz et al., 7 Anticancer Research, 927-36 (1987)		✓
N	Wright et al., 1 Urological Oncology, 18-28 (1995)		✓
O	Horoszewicz et al., 43 Cancer Research, 1809-18 (1983)		✓
P	Stone et al., 21 Int'l J. of Cancer, 274-81 (1978)		✓
Q	Kaign et al., 17 Investigations in Urology, 16-23 (1979)		✓
R	"Gene Delivery Systems" OECD Documents, 2 rue Andre-Pascal 75775 Paris Cedex 16 France (1996)		✓
S	Harlow et al. Antibodies: A Laboratory Manual, Cold Spring Harbor NY 346-355 (1988)		✓
T	Voller et al., Bull. World Health Organ., 53, 55 (1976)		✓
U	Avrameas et al., 8 Scand. J. Immunol. No. 7 Suppl. 7 (1978)		✓
V	Wilson et al., Immunofluorescence and related staining techniques, Elsevier/North Holland Biomedical Press, Amsterdam 215 (1978)		✓
W	Hijmans et al., 4 Clin. Exp. Immunol. 457 (1969)		✓
X	Goding et al., 13 J. Immunol. Meth., 215 (1976)		✓

Examiner Signature	<i>John P. Cullen</i>	Date Considered	12/19/2004
--------------------	-----------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.